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Background. Laparoscopic antireﬂux surgery has shown to be eﬀective in controlling gastroesophageal reﬂux (GERD). Yet, a
universally accepted deﬁnition and evaluation for treatment success/failure in GERD is still controversial. The purpose of this
paper is to assess if and how the outcome variables used in the diﬀerent studies could possibly lead to an homogeneous appraisal
of the limits and indications of LARS. Methods. We analyzed papers focusing on the eﬃcacy and outcome of LARS and published
in English literature over the last 10 years. Results. Symptoms scores and outcome variables reported are dissimilar and not
uniform. The most consistent parameter was patient’s satisfaction (mean satisfaction rate: 88.9%). Antireﬂux medications are not
a trustworthy outcome index. Endoscopy and esophageal manometry do not appear very helpful. Twenty-four hours pH metry
is recommended in patients diﬃcult to manage for recurrent typical symptoms. Conclusions. More uniform symptoms scales and
qualityoflifetoolsareneededforassessingtheclinicaloutcomeafterlaparoscopicantireﬂuxsurgery.Inaneraofcostcontainment,
objective evaluation tests should be more speciﬁcally addressed. Relying on patient’s satisfaction may be ambiguous, yet from this
study it can be considered a practical and simple tool.
1.Introduction
Laparoscopic antireﬂux surgery (LARS) has shown to be
eﬀective in controlling gastroesophageal reﬂux [1, 2]. How-
ever, a universally accepted deﬁnition for treatment suc-
cess/failure in gastroesophageal reﬂux disease (GERD) is not
yet available: objective evaluation of symptoms, response to
treatment,anddeﬁnitionoftreatmentfailureareallstillcon-
troversial. A substantial number of the patients after sur-
gery still take antireﬂux medications (ARMs) [3–5], with
percentages ranging from 62% to 15–20% after 9 and 4-5
yearsoffollowup,respectively[6–12].ARMuseisperformed
on the assumption that foregut symptoms in a patient
after fundoplication are consequent to a failed operation
and based on the assumption that a diagnosis of recurrent
reﬂux can be made conﬁdently from the clinical ﬁndings
[13, 14]. However, most patients taking acid suppressive
medications after antireﬂux surgery do not reveal any
abnormal esophageal acid exposure [15], and the presence
of symptoms alone may not seem to be a good reason to start
an antacid treatment. Therefore, the prescription of ARM
frequently seems inappropriate and does not always indicate
that surgical therapy has failed.
Reports dealing with the clinical outcome after LARS,
either concentrate on symptomatic results, patient’s satis-
faction, and quality of life, on the percentage of patients
taking ARM, or on the objective evaluation of the esophageal
function and acid exposure. Yet, there is not agreement on
how should a successful outcome be deﬁned and how could
the consequent therapeutic approach be directed.
On this background, we felt worthwhile to analyze the
recentliterature,mainly focusedontheeﬃcacyand outcome
of LARS. The purpose of this paper is therefore
(i) to assess if and how the outcome variables used in
the diﬀerent studies could possibly lead, in spite of2 Minimally Invasive Surgery
their complexity, to an homogeneous appraisal of the
limits and indications of LARS in the management of
GERD,
(ii) how these outcome evaluations could be better
interpreted in order to identify failures of treatment,
(iii) topossiblyextrapolateandsuggestaﬂowchartforthe
postoperative evaluation after LARS.
2. Methods
In order to evaluate criteria and deﬁnition of a successful
clinical outcome after LARS, we analyzed studies, published
after 2000, which were speciﬁcally performed to assess reﬂux
symptoms, medication assumption, satisfaction to surgery,
evaluation of quality of life, and objective esophageal tests
after LARS. Speciﬁcally, for each study, it was taken into
account:
(i) parameters utilized to assess the clinical outcome,
that is, clinical evaluation or interview, phone
interview, symptoms questionnaire or others (QoL,
GIQLI, HRQL, GSRS, PGWB), analysis of hospital
data bases, level of satisfaction;
(ii) incidence of GERD and not GERD-related symp-
toms;
(iii) use of ARM (either continuous or occasional) for
GERD-related and not GERD symptoms;
(iv) response to medications and, when speciﬁed, the
main prescriptor (family physician, gastroenterolo-
gist, surgeon);
(v) objective esophageal tests (endoscopy, esophageal
manometry, 24-hour esophageal pH-metry) when
performed.
3. Results
Thirty-four papers [2–6, 8, 11, 14–40] concerning clinical
outcome after LARS were evaluated. The total number of
patients included in this review was 7599, with a follow-
up ranging from a minimum of 6 months to 12 years. The
ﬁrst author was a gastroenterologist in 7 (21.8%) papers
and a surgeon in 26. Twenty-ﬁve studies came from highly
specialized or university hospitals, 2 from VA cooperative
studies[6,26],3fromcooperativestudiesbetweenuniversity
hospitals [23, 36, 39], and 3 from community hospitals
[3, 26, 28].
3.1. Clinical Assessment Tools. Diﬀerent questionnaires were
proposed to the patients in 23 studies, by clinical, phone,
or postal interview, which are listed in Table 1. Patient’s ap-
praisal was done by clinical evaluation during the follow-up
visit in 7 studies, while one investigation was based on the
review of VA clinical database of the outpatients clinics.
Patients satisfaction was speciﬁcally investigated in 15
papers.
3.2. Satisfaction, Quality of Life, and Clinical Symptoms. The
mean percentage of patients satisﬁed by surgery was high
(88.9% ±2.8%).
Ten studies assessed the quality of life after surgery, either
comparing it to preoperative values or to a group of medi-
cally treated patients. The results are showed in Table 2.
Quality of life scores improved after surgery but in only one
study out of 4 the surgical group achieved a signiﬁcantly
better score than the medical group.
GERD symptoms scores showed an improvement after
surgery in all series. However, GERD-related symptoms
(heartburn and/or regurgitation) were still reported in 18.2
±12.3% of patients (range 4–47%) in 21 studies. Not GERD-
related symptoms (including dysphagia, often a new sym-
ptom after surgery) were reported in 27.7 ± 18.8%, in 14
papers.
3.3. Antireﬂux Medications. ARMs for GERD-related symp-
toms after LARS are taken by 34.9% ± 15.9 of patients,
in 21 (62.5%) studies (Table 3). Only 6 studies (18.7%)
diﬀerentiated continuous from occasional treatment, and
only3studiesindicatedthemainprescriber(GP,gastroenter-
ologist, surgeon, self-prescription). Moreover, only 5 studies
indicated the rate of successful response to ARM for GERD-
related symptoms (ranging from 25 to 95%), and only one
gave details about the response to medical treatment for not
GERD-related symptoms.
3.4. Endoscopy. The results of endoscopic examination as a
part of the clinical assessment after surgery were reported in
8 studies (26.6%).
3.5. Esophageal Manometry. This test, speciﬁcally performed
in 7 studies [8, 11, 15, 17, 19, 20, 38], showed a signiﬁcant
increase of lower esophageal sphincter (LES) pressure after
surgery both in symptomatic and asymptomatic patients
[19], usually at a short-term evaluation, with a drop in the
long term in some studies [20] but not in others [11]. Some
[15] did not observe any predictable change of esophageal
peristalsis,whiledisorderedesophagealmotilitywasreported
in 9% of the patients [19] (no mention of preoperative
features). In one study [38]i th a sb e e nf o u n dt h a tp a t i e n t s
with either a low or high postoperative LES pressure have a
similar long-term symptoms proﬁle with a signiﬁcant linear
correlation between diﬀerence in postoperative LES pressure
and long-term symptom score for heartburn, dysphagia, and
regurgitation.Finally,nocorrelationhasbeenfoundbetween
postoperative LES and symptoms or 24-hour pH recording
[17].
3.6. 24 Hours Esophageal pH-metry. Patients were submitted
to esophageal 24-hour pH-metry after LARS in 18 (54.5%)
studies, with diﬀerent indications and results (Table 4). The
mean percentage of patients with abnormal score was 24%
(range 16–62%), but the percentage of patients submitted to
this test was very variable, ranging from 16 to 100%. The
mean percentage of abnormal results among those taking
ARM was 32% (Table 5).Minimally Invasive Surgery 3
Table 1: Parameters used for patients evaluation and number of studies.
Parameters Number of studies Refs
Questionnaires
GERD symptoms score 23
[3–6, 8, 11, 15, 16, 18, 20, 24, 25, 27, 29, 32–37, 39, 40]
Gastroesophageal Reﬂux Disease Activity Index (GRACY)
Digestive Health Survey Instrument
Gastrointestinal Symptoms Rating Scale (GSRS)
Jamieson Score
Gastrointestinal Quality of Life Index (GIQLI) 3 [25, 27, 33]
Psychological General Well-Being Index (PGWBI) 2 [23, 39]
Short-form 36 (SF 36) 2 [6, 22]
Health-Related Quality of Life (HRQL) 1 [34]
Well-Being Score (WBS) 1 [2]
Visual Analogue Score (VAS) 1 [11]
Patients satisfaction 16 [2–6, 11, 18, 20, 24, 29, 32–35, 38]
VA clinical data base (outpatients clinics) 1 [26]
Clinical assessment at follow-up visit 7 [4, 11, 19, 22, 31, 38, 39]
Objective esophageal tests
Endoscopy 8 [3, 6, 14, 15, 22, 23, 30, 31]
Esophageal manometry 7 [8, 11, 15, 17, 19, 20, 38]
24-h Esophageal pH-metry 18 [6, 8, 11, 14–20, 27, 32–37, 40]
Table 2: HRQoL Assessment with diﬀerent questionnaires and their results.
Author Year Ref. Tools Results
Spechler et al. 2001 [6] SF-36 No signiﬁcant diﬀerence between medical and surgical group
Bammer et al. 2001 [2] WBS Improved signiﬁcantly at more than 5 years of followup
Olberg et al. 2005 [23] PGWBI No signiﬁcant diﬀerence between medical and surgical group
Contini and Scarpignato 2004 [22] SF-36 Normal score 2 years after LARS
Ciovica et al. 2006 [27] GIQLI + HRQL QoL normalized after LARS and signiﬁcantly higher than a
medically treated group
Dallemagne et al. 2006 [25] GIQLI Signiﬁcantly better than preoperatively at 10 years
Draaisma et al. 2006 [11] VAS 30% improvement after surgery
Gee et al. 2008 [34]G E R D −HRQL Near normal score at long-term followup
Fein et al. 2008 [33] GIQLI Signiﬁcant improvement of the QoL after 10 years
Lundell et al. 2009 [39]P G W B I Similar to that of normal population in both surgical and
medical group at 12 years
VAS: Visual Analogue Scale.
4. Discussion
Laparoscopic antireﬂux surgery currently represents the
golden standard in the surgical management of GERD, being
a viable alternative to medical treatment, with minimal
morbidity and mortality [8–10]. However, an accurate and
universally accepted evaluation of the clinical outcome after
LARS is still a critical issue. How to assess satisfaction and
subjective symptoms of the patients, how and when to
evaluate objectively the outcome in order to deﬁne an opti-
mal response to surgery, and, ﬁnally, the connotation of a
treatment failure, are still controversial topics. The surgical
reports analyzed may be divided in 4 diﬀerent groups:
(i) papers concentrated on perioperative morbidity and
mortality or on technical problems, that is, type of
fundoplication and their side eﬀects and less deeply
focused on a clear-cut long-term appraisal of the
clinical outcome;
(ii) papers dealing with long-term symptomatic results,
taking into account symptoms score, quality of life,
and patient’s satisfaction;
(iii) papers highlightening the large number of patients
taking ARM after LARS, generally prescribed on the
base of the false assumption that foregut symptoms
in a patient after fundoplication are consequent to a
failed operation;
(iv) papers concentrated on the comparison of clinical
outcome between medically and surgically treated
patient population.4 Minimally Invasive Surgery
Table 3: Incidence of ARM use after LARS.
Authors Year Ref. Followup
(yrs)
Patients on
ARM (%)
Spechler et al. 2001 [6] 6.4 23/37 (62%)
Bammer et al. 2001 [2] 6.3 24/171 (14%)
Booth et al. 2002 [18] 2.0 19/140 (14%)
Lord et al. 2002 [14] 2.4 37/86 (43%)
Anvari and
Allen 2003 [20] 5.0 21/181 (12%)
Bloomston et al. 2003 [5] 5.0 31/84 (37%)
Papasavas et al. 2003 [8] 2.6 56/297 (19%)
Vakil et al. 2003 [3] 1.7 26/80 (33%)
Velanovich et al. 2003 [21] 2.4 16/122 (13%)
Galvani et al. 2003 [15] 1.5 62/124 (50%)
Contini and
Scarpignato 2004 [22] 2 13/50 (26%)
Tucker et al. 2005 [24] 4.1 58/119 (49%)
Thibault et al. 2006 [28] 3.6 38/121 (31%)
Dominitz et al. 2006 [26]4 . 5 1199/2406
(49.8%)
Draaisma 2006 [11] 6 11/79 (13.9%)
Bonatti et al. 2007 [4] 2.4 37/94 (39%)
Zaninotto et al. 2007 [31] 8.0 30/145 (21%)
Wijnhoven et al. 2008 [36] 5.9 312/844 (37%)
Oelschlager
et al. 2008 [35] 5.7 119/288 (41%)
Thompson et al. 2009 [40] 4.6 42/69 (60.8%)
Lundell et al. 2009 [39] 12 55/144 (38%)
Mean = 34.9%
Clearly, this paper has inherent limits: the subjective
choice of the reports to evaluate and the fact that it is neither
a meta-analysis nor a systematic review of the whole liter-
ature. It mirrors, however, the current practice. Moreover,
while most papers examined are coming from specialized
andhigh-volume surgicalcentersforLARS,othersreportthe
result from community hospitals [28]o rf r o mc o o p e r a t i v e
studies in hospitals at various levels of experience [6, 23]. It
is well known that surgeon’s experience does matter and that
outcomes of laparoscopic fundoplication in routine clinical
practice are poorer than those reported by referral centres
[3]. It was therefore not in the aims of this study to evaluate
surgical results but rather to compare and highlight the
diﬀerence/homogeneity of postoperative evaluations and to
assess their clinical relevance.
4.1. Clinical Assessment. Only paper [8] speciﬁcally indicate
a clinical interview as a part of the evaluation of postopera-
tive symptoms. Most studies relied on mailed questionnaire
orphoneintervieworevenontheadministrativeandclinical
database of outpatients clinics. Four diﬀerent symptoms
scoreswereused.Allhavebeensomewayvalidatedforclinical
practice, but this disparity in the analysis tools certainly
reveals a rather unstandardized approach to symptoms’
evaluation. Moreover, the way the information is collected as
wellasthecompletenessofthefollowup,sometimesverylow,
mayinﬂuencetheresultsandmayaccountforsomeapparent
diﬀerences in the clinical outcome, with a wide variation of
the typical GERD-related symptoms (i.e., heartburn and/or
regurgitation), ranging from 4.8 to 30% amongst the papers
examined. Studies relying solely on mailed questionnaires
may falsely elevate success rates, especially if followup is
incomplete, and patients with worse outcomes may not be
motivated to return the questionnaires [41]. In addition,
outcomes reported at telephone interview may be more
favorable, as well as there is a signiﬁcant risk of bias in
reporting of surgical outcomes when incomplete data are
analyzed. The limitation inherent to outcome’s com-parison
between diﬀerent groups applying diﬀerent data collection
has already been outlined [41] and recently it has been
strongly recommended the development of validated out-
come instruments [42, 43].
The relevance of the presence of symptoms in the evalua-
tion of clinical outcome may also be questioned, being often
independent on an objective evidence of persistent GE reﬂux
[44]. Symptomatic assessment has been shown to have low
sensitivity and low positive predictive value for abnormal
postoperative 24-hour pH-metry. Hence, it might be mis-
leading to report a successful outcome after LARS, relying
mainlyonsymptoms,whosesolepresenceisapoorindicator
of recurrent reﬂux disease.
Assessment of quality of life has also been employed
as outcome measure after antireﬂux surgery. In this study,
we found that six diﬀerent questionnaires were used to
analyze the QoL, showing again a lack of homogeneity and
standardization. In spite of this, results are consistent, and
quality of life seems to improve uniformly after surgery
in all reports, even in the long term, achieving the same
scores observed in a normal sample population or in the
group of medically treated patients. Although symptomatic
(heartburn) patients, with or without a positive pH study,
did not show any diﬀerent quality of life score after surgery
[40], this parameter measured by a validated (and uniform)
surveyinstrumentcouldperhapsbeasimportantasobjective
measurements of the esophageal function in assessing the
clinical status of the patients after LARS.
Thepercentageofpatientssatisﬁedwithsurgerywasgen-
erally high. Satisfaction is clearly linked to the improvement
or not of quality of life and of course to the presence/absence
of symptoms, severe symptoms being usually associated to a
signiﬁcant decrease in patient’s satisfaction [32]. It is worth-
while mentioning that in a study [3], the satisfaction rate in
patients without resolution of the symptoms was 69%. The
use of ARMs does not inﬂuence signiﬁcantly the satisfaction
rate,thussuggestingthatoftentheindicationsforthesedrugs
are for vague and nonspeciﬁc symptoms, together with a low
threshold by the patients for reinitiating medical treatment.
In reality, a high proportion of patients, who complain
moderate symptoms or side eﬀects following surgery or who
still require regular medication, are of the opinion that a
fundoplication was to some extent advantageous. It comes
out that relying on satisfaction only for a successful clinical
outcome may be ambiguous and that it is needed a clear-
cut deﬁnition or uniform score for satisfaction, a parameterMinimally Invasive Surgery 5
Table 4: Postoperative 24 hrs pH-metry. Indications and results.
Authors Year Ref. Pts submitted to
pH-metry (%) Indications Results
Franz´ en et al. 1999 [16] 67/101 (66.3%) Follow-up 19.4% abnormal score
Spechler et al. 2001 [6] 10/37 (27%) Follow-up
No statistical diﬀerence between
medical and surgical group.
Small sample. Results
inconclusive.
Lord et al. 2002 [14] 86/86 (100%)
Symptomatic
patients after
LARS
23% abnormal score
Arca et al. 2002 [17] 28/46 (49%) Follow-up 28% abnormal score
Booth et al. 2002 [18] 109/175 (78%) Follow-up 5% abnormal score
Khajanchee
et al. 2002 [19] 209/209 (100%) Follow-up 16.7% abnormal score
Galvani et al. 2003 [15] 124/124 (100%)
Symptomatic
patients after
LARS
39% abnormal score;
Gee et al. 2008 [34] 20/191 (10.4%) Follow-up
(ARM) 70% abnormal result
Anvari and
Allen 2003 [20] 181/332 (54.5%) Follow-up Mean acid reﬂux score
signiﬁcantly lower than preop
Papasavas
et al. 2003 [8] 93/297 (31.3%) Follow-up Average percentage of exposed
time <4 was signiﬁcantly reduced
Ciovica et al. 2006 [27] 351/351 (100%) Follow-up 10% Abnormal score
Draaisma
et al. 2006 [11] ?/79 Follow-up 12.5% Abnormal score
Morgenthal
et al. 2007 [32] /166 Follow-up 14% abnormal score in pts on
ARM (3/21)
Oelschlager
et al. 2008 [35] 58/288 (20.1%) Follow-up
(heartburn) 22% abnormal result
Wijnhoven
et al. 2008 [36] 139/844 (16.4%)
Patients
taking ARM
after LARS
22.3% abnormal results
Boddy et al. 2008 [37] 106/145 (73.1%) Follow-up (4
months)
No correlation between pH
scores and symptoms score
Fein et al. 2008 [33] 67/99 (67.6%) Follow-up 33% of pts with heartburn had
recurrent reﬂux
Thompson
et al. 2009 [40] 69/69 (100%)
Symptomatic
patients after
LARS
22% Abnormal score
Table 5: Abnormal esophageal exposure to acid in patients taking ARM after LARS.
Authors Year Ref. Followup (months) Pts with abnormal pH score (%)
Booth et al. 2002 [18] 24 7/19 (36.8%)
Lord et al. 2002 [14] 27.8 9/37 (24.3%)
Galvani et al. 2003 [15] 17 48/124 (39.0%)
Anvari and Allen 2003 [20] 60 9/21 (42.8%)
Draaisma et al. 2006 [11] 60 Absence of correlation between the use of PPIs and documented reﬂux symptoms
Thompson et al. 2009 [40] 44 17/53 (32%)
Wijnhoven et al. 2008 [36] 70.8 16/61 (26.2%)
Fein et al. 2008 [33] 24 NA (42%)
Thompson et al. 2009 [40] 55 7/42 (16.6%)
Mean = 32.4%6 Minimally Invasive Surgery
which may reward the surgeon but cannot probably be taken
as a precise and reliable index of a successful LARS.
4.2. Antireﬂux Medications. One third of the patients is
taking ARM after LARS in our review, but only 6 studies
precise if the use of ARMs was regular or occasional [3, 4, 22,
23,27,36].Arecentmeta-analysisofRCTs[45]foundthat—
after antireﬂux surgery—14% of patients still require ARMs.
This ﬁgure increases with the duration of followup, and up
to one third of patients required acid-lowering drugs after
10 years. The data from nonrandomized studies [46], which
are higher than data from randomized studies (i.e., 20% of
patients under ARMs), are probably more representative of
the current clinical practice.
Some authors consider medication use as an outcome
measure for successful antireﬂux surgery [6], while others
suggest that use of ARM does not correlate with true recur-
rent reﬂux in the majority of the patients [18, 20, 32]a n d
does not necessarily indicate a failure of theprocedure. Asig-
niﬁcantproportionofpatientstakingmedicationsafteroper-
ation are using them to relieve nonreﬂux-related symptoms,
and only one third of patients of them showed an abnormal
exposure to acid (Table 5). In one study, 79% of patients on
ARM took drugs for abdominal or chest symptoms thought
to be unrelated to reﬂux, often pre-existing to surgery [2].
Many of these patients may restart medications on their own
or have them prescribed empirically without proven needs.
An analysis of an administrative database, likely addressed to
patients receiving care from the usual caregivers than from
expert providers, highlights the likelihood of continued anti-
reﬂux medications after surgery in up to 50% of patients
[26]. Therefore, not only the high postoperative use of ARM
is questionable and often incorrect, but also it may not be
a reliable and trustworthy tool for the evaluation of surgical
outcome.
4.3. Objective Evaluation of the Esophagus. In general, objec-
tive outcome measures, probably the better way to evaluate
the outcome, are not used frequently, especially in the
long-term followup, due to the diﬃculty of the patients
to accept uncomfortable procedures, and this consequently
bringsalesscompletefollowup.Usually,postoperativeobjec-
tive testing is recommended in presence of persistent or
recurrent symptoms after LARS and not in asymptomatic
patients, which is realistic in an era of cost containment.
However, this approach may not be appropriate, since many
symptomatic patients do not show any pathologic reﬂux at
24 pH-metry; conversely, asymptomatic patient may have
signiﬁcant pathological reﬂux [19].
4.4.Endoscopy. UpperGIendoscopywascarriedoutinalow
percentage of patient’s population and failed to provide any
useful critical information. Relationship with symptoms was
poor, and the evaluation and grading of esophageal lesions
(when present) were found to be extremely subjective. As a
consequence, “standard” endoscopic examination is unlikely
to inﬂuence postoperative management.
4.5. Esophageal Manometry. While a signiﬁcant postopera-
tive increase of LES pressure has been found in successful,
asymptomatic patients [47], other investigations failed to
show any signiﬁcant diﬀerence in pressure increase between
symptomatic and asymptomatic patients [48]. Moreover,
no correlation has been found between postoperative LES
pressure and symptoms or 24 hour pH-metry results [17].
Taking into account the inconsistent manometric ﬁndings
and the diﬃcult acceptance of the procedure by the patients,
itishardtoproposeitasaregularandtrustablepostoperative
test, its role being secondary to esophageal pH recording in
symptomatic patients.
4.6. 24 Hour Esophageal pH-metry. In the papers examined,
postoperative 24-hour pH-metry has been the most fre-
quently performed objective test, mainly to identify patients
with true recurrent gastroesophageal reﬂux. The reproduci-
bility of 24-hour pH monitoring is essential to make it re-
liable. Actually, a concordance rate of 96% in repeated test
was recently reported [40]. Ideally, patients with recurring
symptoms should undergo a 24-hour pH probe study for an
objective evaluation and quantitation of acidic reﬂux. We do
not feel that such test should be recommended postopera-
tively on a routine basis. Indeed, ﬁnding a positive test in
an asymptomatic patient would be challenging due to the
lack of established guidelines in this clinical setting. On the
other hand, successful operations, as demonstrated by a nor-
mal exposure to acid, may not eliminate all reﬂux-related
symptoms. Although nonacid reﬂux could be responsible
for symptoms, it has been shown to be very uncommon
[49]. Moreover, a recent investigation [50] reported that
persistent symptoms are neither caused by acid nor by
weakly acidic reﬂux, but rather by abnormal air handling.
To investigate weakly acidic or nonacidic reﬂux-related sym-
ptoms, a combined pH-impedance study is needed, but this
test is more costly and technically demanding.
5. Conclusions
The evaluation of eﬃcacy of LARS as a permanent treatment
for GERD deﬁnitely depends on determining what should
be considered a successful outcome. This study high-lights
the need to be careful when considering clinical outcomes
reported after antireﬂux surgery. The complexity in captur-
ing data is evident. Not only symptoms assessment may be
considered not appropriate in some studies, but also symp-
toms scores and outcome variables reported in diﬀerent
studies are dissimilar, making a plea for more uniform
symptoms scales and quality of life tools. This would be
of utmost importance in the clinical practice, where either
gastroenterologistsorprimarycarephysiciansneedtounder-
standthatmostpatients complaining ofpostoperative symp-
toms do not have pathologic reﬂux.
Relying on patient’s satisfaction to deﬁne a successful
surgical outcome may be ambiguous and cannot probably be
takenasapreciseandreliableindexofasuccessfulprocedure,
yetfromthisstudyitcanbeconsideredapracticalandsimple
tool, with uniform results.Minimally Invasive Surgery 7
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